Genetic prodrug activation therapy

被引:26
|
作者
Rigg, A
Sikora, K
机构
[1] ICRF Molecular Oncology Unit, Imperial College of Medicine, Hammersmith Hospital, London W12 0NN, Du Cane Road
来源
MOLECULAR MEDICINE TODAY | 1997年 / 3卷 / 08期
关键词
D O I
10.1016/S1357-4310(97)01082-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Genetic prodrug activation therapy shows promise as a therapeutic option for the treatment of cancer as well as a variety of other diseases. it involves the insertion of a gene encoding a drug-metabolizing enzyme into cells and the systemic administration of a prodrug. The prodrug is converted to a cytotoxic agent by the action of the expressed enzyme. To ensure that the enzyme is only expressed in the targeted subset of cells, the transcriptional apparatus of a gene that is unique to this subset is used to regulate the gene encoding the drug-metabolizing enzyme. As with all types of gene therapy, one of the major obstacles to successful clinical treatment is the development of safe and effective gene delivery systems.
引用
收藏
页码:359 / 366
页数:8
相关论文
共 50 条
  • [21] Theranostic Heterodimeric Prodrug with Dual-Channel Fluorescence Turn-On and Dual-Prodrug Activation for Synergistic Cancer Therapy
    Jiang, Maolin
    Wang, Kewei
    Xiao, Xuan
    Zong, Qingyu
    Zheng, Rui
    Yuan, Youyong
    ADVANCED HEALTHCARE MATERIALS, 2021, 10 (21)
  • [22] Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques
    Eaton, JD
    Perry, MJA
    Todryk, SM
    Mazucco, RA
    Kirby, RS
    Griffiths, JR
    Dalgleish, AG
    GENE THERAPY, 2001, 8 (07) : 557 - 567
  • [23] Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques
    J D Eaton
    M J A Perry
    S M Todryk
    R A Mazucco
    R S Kirby
    J R Griffiths
    A G Dalgleish
    Gene Therapy, 2001, 8 : 557 - 567
  • [24] Ultrasound-Controlled Prodrug Activation: Emerging Strategies in Polymer Mechanochemistry and Sonodynamic Therapy
    Fu, Xuancheng
    Hu, Xiaoran
    ACS APPLIED BIO MATERIALS, 2024, 7 (12): : 8040 - 8058
  • [25] Immune Bystander Effect in Prodrug Activation Gene Therapy with Nitroreductase and CB1954
    Searle, Peter F.
    Salman, Asmaa
    Viney, Richard
    Patel, Prashant
    Onion, David
    James, Nicholas D.
    Porfiri, Emilio
    Mautner, Vivien
    HUMAN GENE THERAPY, 2010, 21 (04) : 522 - 523
  • [26] Tetrazine-Mediated Bioorthogonal System for Prodrug Activation, Photothermal Therapy, and Optoacoustic Imaging
    Xie, Xin
    Li, Bowen
    Wang, Jie
    Zhan, Chenyue
    Huang, Yong
    Zeng, Fang
    Wu, Shuizhu
    ACS APPLIED MATERIALS & INTERFACES, 2019, 11 (45) : 41875 - 41888
  • [27] Fibroblast activation protein (FAP) activated anti-stromal prodrug therapy for cancer
    Aggarwal, S.
    Cole, T.
    Brennen, W. N.
    Topaloglu, O.
    Schneider, E.
    Cotter, R.
    Denmeade, S. R.
    EJC SUPPLEMENTS, 2006, 4 (12): : 160 - 160
  • [28] Selection of nitroreductase variants with increased efficiency of CB1954 activation, for use in prodrug activation gene therapy for cancer
    Searle, Peter
    Vass, Simon
    Guise, Chris
    Jaberi-Pour, Mansooreh
    Jarrom, David
    Hyde, Eva
    HUMAN GENE THERAPY, 2007, 18 (10) : 1000 - 1001
  • [29] DT-diaphorase and prodrug activation
    Chen, SA
    BRITISH JOURNAL OF CANCER, 2002, 86 : S11 - S11
  • [30] PRODRUG ACTIVATION VIA CATALYTIC ANTIBODIES
    MIYASHITA, H
    HARA, T
    TANIMURA, R
    KIKUCHI, M
    FUJII, I
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 195 - 195